NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives $36.75 Consensus PT from Analysts

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has been given a consensus recommendation of “Hold” by the six ratings firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $36.75.

NRXP has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. D. Boral Capital reissued a “buy” rating and issued a $34.00 price target on shares of NRx Pharmaceuticals in a research note on Tuesday, February 17th. Ascendiant Capital Markets restated a “buy” rating and set a $48.00 price objective (up from $47.00) on shares of NRx Pharmaceuticals in a research report on Friday, January 2nd. BTIG Research reaffirmed a “buy” rating and set a $25.00 price objective on shares of NRx Pharmaceuticals in a report on Wednesday, February 18th. Finally, HC Wainwright restated a “buy” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, January 21st.

Institutional Trading of NRx Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. One Wealth Management Investment & Advisory Services LLC raised its stake in NRx Pharmaceuticals by 35.3% in the 4th quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock valued at $103,000 after purchasing an additional 9,882 shares during the last quarter. State Street Corp boosted its stake in NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock worth $236,000 after purchasing an additional 10,700 shares during the last quarter. Ethos Financial Group LLC purchased a new stake in shares of NRx Pharmaceuticals during the third quarter worth $39,000. Sjbenen Advisory LLC acquired a new stake in shares of NRx Pharmaceuticals in the fourth quarter valued at about $41,000. Finally, Two Sigma Investments LP lifted its stake in shares of NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after buying an additional 20,880 shares in the last quarter. 4.27% of the stock is owned by institutional investors and hedge funds.

NRx Pharmaceuticals Stock Down 4.3%

Shares of NRx Pharmaceuticals stock opened at $1.76 on Friday. The firm has a market cap of $56.09 million, a PE ratio of -0.75 and a beta of 1.92. NRx Pharmaceuticals has a twelve month low of $1.58 and a twelve month high of $3.84. The business has a 50-day moving average price of $2.17 and a 200 day moving average price of $2.54.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.